GSK opens S$130m facilities in Jurong
New plant and expanded building will step up pharmaceutical firm's output of active ingredients in its HIV medication
Add BT as a preferred source
Singapore
PHARMACEUTICAL giant GlaxoSmithKline (GSK) unveiled a new, fully automated continuous manufacturing facility and an expanded production building at its Jurong site on Friday, worth a total of S$130 million.
The site upgrades will accelerate GSK's global supply chain and, in particular, its production of active pharmaceutical ingredients (APIs) such as Dolutegravir and Lamivudine, key assets in GSK's HIV medication.
TRENDING NOW
CSE Global independent director quits after clashes with chairman Eugene Lai over board refresh
Cat A COE rate exceeds Cat B for third time in 4 months; premiums largely down
What’s wrong with Orchard Road? Experts weigh in on the street’s cachet and its future
Singapore workers experiencing rising anxiety; signs of fallout from pressure to use AI
